Charles River Laboratories Announces 2024 Annual Meeting of Shareholders

TL;DR

<b>Charles River Laboratories will hold its 2024 Annual Meeting on May 8, 2024, to elect directors, vote on executive compensation, and ratify auditor selection.</b>

AI Summary

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) filed a Proxy Statement (DEF 14A) with the SEC on March 29, 2024. Annual Meeting scheduled for May 8, 2024, at 8:00 a.m. in Boston, MA. Eleven director nominees are up for election. Shareholders will vote on an advisory resolution for executive compensation. PricewaterhouseCoopers LLP is proposed for ratification as the independent auditor for FY2024. A shareholder proposal will also be presented for a vote.

Why It Matters

For investors and stakeholders tracking CHARLES RIVER LABORATORIES INTERNATIONAL, INC., this filing contains several important signals. Shareholders have the opportunity to influence corporate governance by voting on director nominees and executive compensation. The ratification of the independent auditor ensures continued oversight of the company's financial reporting.

Risk Assessment

Risk Level: low — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. shows low risk based on this filing. The filing is a routine proxy statement for an annual shareholder meeting, with no immediate financial or operational risks indicated.

Analyst Insight

Shareholders should review the director nominees and executive compensation proposals before the May 8, 2024 meeting to cast an informed vote.

Key Numbers

• 11 — Director Nominees (Number of persons nominated for election to the Board of Directors.)
• 2024-05-08 — Annual Meeting Date (Date of the 2024 Annual Meeting of Shareholders.)
• 8:00 a.m. — Annual Meeting Time (Time of the 2024 Annual Meeting of Shareholders.)

Key Players & Entities

• Charles River Laboratories International, Inc. (company) — Registrant
• James C. Foster (person) — Chair, President and Chief Executive Officer
• PricewaterhouseCoopers LLP (company) — independent registered public accounting firm
• Cooley LLP (company) — location of Annual Meeting

FAQ

Industry Context

Charles River Laboratories International, Inc. operates in the life sciences industry, providing essential products and services to pharmaceutical and biotechnology companies.

Regulatory Implications

The filing is made under Section 14(a) of the Securities Exchange Act of 1934, which governs the solicitation of proxies.

What Investors Should Do

1. Review the list of 11 director nominees and their qualifications.
2. Understand the advisory resolution on executive compensation and the company's rationale.
3. Confirm the ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2024.

Key Dates

• 2024-05-08: Annual Meeting of Shareholders — Shareholders will vote on director nominees, executive compensation, and auditor ratification.

Year-Over-Year Comparison

This is the definitive proxy statement for the 2024 Annual Meeting, following the typical schedule for such filings.

Key Financial Figures

• $683.9 million — r share from continuing operations, and $683.9 million in cash flow relating to operating acti
• $13,500 — n of proxies at a cost of approximately $13,500 plus reimbursement of expenses. Votes

Filing Documents

• tm242687-d2_def14a.htm (DEF 14A) — 2471KB
• lg_charlesriver-4c.jpg (GRAPHIC) — 8KB
• sg_jamescfoster-bw.jpg (GRAPHIC) — 21KB
• sg_matthewldaniel-bw.jpg (GRAPHIC) — 9KB
• ic_member-bw.jpg (GRAPHIC) — 2KB
• ic_tick-bw.jpg (GRAPHIC) — 2KB
• ic_committe-bw.jpg (GRAPHIC) — 2KB
• ph_jamescfosternew-bwlr.jpg (GRAPHIC) — 12KB
• ph_nancyandrews-bwlr.jpg (GRAPHIC) — 22KB
• ph_robertbertolini-bw.jpg (GRAPHIC) — 12KB
• ph_reshemakempspolanco-bwlr.jpg (GRAPHIC) — 15KB
• ph_deborahtkochevar-bwlr.jpg (GRAPHIC) — 11KB
• ph_georgellado-bwlr.jpg (GRAPHIC) — 20KB
• ph_martinmackay-bw.jpg (GRAPHIC) — 10KB
• ph_georgemassaro-bwlr.jpg (GRAPHIC) — 9KB
• ph_craigthompson-bwlr.jpg (GRAPHIC) — 18KB
• ph_richardwallman-bwlr.jpg (GRAPHIC) — 11KB
• ph_virginiawilson-bwlr.jpg (GRAPHIC) — 15KB
• pc_diverse-bw.jpg (GRAPHIC) — 9KB
• lc_peergroup-bw.jpg (GRAPHIC) — 82KB
• bc_ceocomp-bwlr.jpg (GRAPHIC) — 90KB
• bc_tsr-bw.jpg (GRAPHIC) — 54KB
• lc_crltsr-bw.jpg (GRAPHIC) — 29KB
• bc_nongappeps-bw.jpg (GRAPHIC) — 53KB
• bc_netincome-bw.jpg (GRAPHIC) — 75KB
• px_24charlesriverpg01-bw.jpg (GRAPHIC) — 237KB
• px_24charlesriverpg02-bw.jpg (GRAPHIC) — 262KB
• 0001104659-24-040854.txt (&nbsp;) — 6207KB
• crl-20231230.xsd (EX-101.SCH) — 9KB
• crl-20231230_def.xml (EX-101.DEF) — 7KB
• crl-20231230_lab.xml (EX-101.LAB) — 27KB
• crl-20231230_pre.xml (EX-101.PRE) — 6KB
• tm242687-d2_def14a_htm.xml (XML) — 251KB

From the Filing

tm242687-1_nonfiling - none - 23.260245s UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under 240.14a-12 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 March 29, 2024 Dear Shareholder, You are cordially invited to attend the 2024 Annual Meeting of Shareholders of Charles River Laboratories International, Inc. to be held at 8:00 a.m. on Wednesday, May 8, 2024, at the offices of Cooley LLP located at 500 Boylston Street, Boston, MA 02116. At the Annual Meeting, eleven (11) persons are nominated for election to our Board of Directors. We will also hold a vote on an advisory resolution on our executive compensation, and ask shareholders to ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for fiscal year 2024. Finally, a shareholder has proposed a resolution as described in the Proxy Statement. Our Board of Directors recommends the approval of the proposals to elect each of the eleven directors, to approve the advisory vote on our executive compensation, to ratify the selection of PricewaterhouseCoopers LLP, and recommends that you vote against the shareholder proposal. Such other business will be transacted as may properly come before the Annual Meeting. Whether you plan to attend the Annual Meeting or not, it is important that your shares are represented. Therefore, we urge you to complete, sign, date and return the enclosed proxy card promptly or use internet voting prior to the Annual Meeting in accordance with the instructions set forth on the card. This will ensure your proper representation at the Annual Meeting. Sincerely, James C. Foster Chair, President and Chief Executive Officer YOUR VOTE IS IMPORTANT. PLEASE VOTE YOUR SHARES PROMPTLY. Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Shareholders to be held on May 8, 2024. This Proxy Statement and our Annual Report to Shareholders are available at www.criver.com/annual2024 . In addition, our Annual Report on Form 10-K for fiscal year 2023 can be found on the same website. CHARLES RIVER LABORATORIES INTERNATIONAL, INC. NOTICE OF ANNUAL MEETING OF SHAREHOLDERS to Be Held on May 8, 2024 To the Shareholders of Charles River Laboratories International, Inc.: NOTICE IS HEREBY GIVEN that the Annual Meeting of Charles River Laboratories International, Inc., a Delaware corporation, will be held on Wednesday, May 8, 2024, at the offices of Cooley LLP located at 500 Boylston Street, Boston, MA 02116 at 8:00 a.m., for the following purposes: 1. To elect each of the eleven (11) persons named in this Proxy Statement to our Board of Directors to hold office until the next Annual Meeting of Shareholders. 2. To approve an advisory vote on our executive compensation. 3. To consider and act upon a proposal to ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 28, 2024. 4. To vote on a shareholder proposal described in this Proxy Statement, if properly presented at the Annual Meeting. 5. To transact such other business as may be properly brought before the Annual Meeting and any adjournments thereof. The Board of Directors has fixed the close of business on March 15, 2024 as the record date for the determination of shareholders entitled to notice of, and to vote at, the Annual Meeting and at any adjournments thereof. All shareholders are cordially invited to attend the Annual Meeting. Attendance at the Annual Meeting will be limited to shareholders and those holding proxies from shareholders. An admission ticket and government-issued picture identification will be required to enter the Annual Meeting. Any individual arriving without an admission ticket will not be admitted to the Annual Meeting unless it can be verified that the individual is a Charles River shareholder as of the record date for the Annual Meeting. Shareholders may obtain an Annual Meeting ticket by writing to the Corporate Secretary, Charles River Laboratories International, Inc., 251 Ballardvale Street, Wilmington, Massachusetts 01887 or by sending an email to the following email ad

View Full Filing

View this DEF 14A filing on SEC EDGAR